UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.